Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00770055
Other study ID # CDR0000592835
Secondary ID P30CA072720CINJ-
Status Completed
Phase N/A
First received October 8, 2008
Last updated January 27, 2011
Start date November 2001
Est. completion date January 2011

Study information

Verified date January 2011
Source Rutgers, The State University of New Jersey
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

RATIONALE: Gathering information about patients with breast cancer over time may help doctors learn more about a patient's use of the internet to find information about treatment, symptom management, and emotional support.

PURPOSE: This clinical trial is studying internet use among women with recurrent metastatic breast cancer.


Description:

OBJECTIVES:

- To document the proportion of women who use the internet to access treatment and symptom management information and to seek emotional support after diagnosis of metastatic recurrent breast cancer.

- To evaluate the association of treatment stage and effectiveness with internet use.

- To evaluate the association of individual differences in patients' demographics, beliefs, emotional functioning, and social and professional support with internet use.

- To evaluate the association of patients' use of the internet to seek resources with their beliefs, emotional functioning, and relationship functioning.

OUTLINE: Patients undergo assessments consisting of paper and pencil questionnaires at four time points. The timing of these assessments is linked to the patient's treatment course and her presumed need to access internet resources for information on cancer, treatment, symptom management, and emotional support. Patients who discontinue regular care at the Cancer Institute of New Jersey site during the course of the study may complete study assessments through phone interviews conducted by a member of the study team.

Patients undergo a baseline survey prior to deciding on a treatment course for their newly progressive disease. Patients complete the first part of the survey to provide information on demographics, beliefs about cancer, mood states, somatic symptoms, and available resources for cancer information and emotional support. Patients complete the second part of the survey, if they have used the internet previously to obtain information and resources about cancer or if they have received cancer information that someone else located on the internet for them, which inquires about patients' internet use, any internet resources they have received from family members, friends, or other people they know, and their own evaluation of these internet resources. Patients undergo the second study assessment after completion of the first course of treatment and prior to initiating course 2 (i.e., 3 to 4 weeks after initiating treatment). The third study assessment occurs within the first 2 weeks after the medical oncologist's first evaluation of treatment response (i.e., 6-9 weeks after initiating treatment). The fourth assessment occurs after the medical oncologist's second evaluation of the patient's response to treatment, following tumor re-staging.

Patients complete several questionnaires during these assessments to provide information about personal characteristics (demographics, physical and psychological well-being, beliefs about cancer and treatment, optimism), social and healthcare networks (perceived social support, social network composition, beliefs about treatment team), and outcomes (use of non-internet cancer information, use of the internet for cancer resources, use of interactive technologies, communication with treatment team and family, evaluation of internet resources).

The following information is extracted from the patients' medical record: stage and node status at primary diagnosis, previous oncology surgeries, previous adjuvant treatments, current menopausal status, treatment at time of recurrence, disease free interval, site(s) of metastasis, and response to current treatment.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date January 2011
Est. primary completion date February 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of recurrent breast cancer meeting either of the following criteria:

- Newly diagnosed metastatic disease

- Recently diagnosed as progressive disease after stable metastatic disease for at least 6 months

- Must have received the same treatment for metastatic breast cancer for at least 3 months

- Have received no treatment for progressive disease OR have begun treatment for progressive disease within the past month

- Patient at the Cancer Institute of New Jersey in New Brunswick or Hamilton, New Jersey

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Menopausal status not specified

- Able to speak and write English

- Free of diseases and cognitive impairments that would interfere with comprehension of the survey instruments or ability to provide informed consent

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Study Design

Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Other:
medical chart review

questionnaire administration

survey administration

Procedure:
psychosocial assessment and care


Locations

Country Name City State
United States Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick New Jersey

Sponsors (2)

Lead Sponsor Collaborator
University of Medicine and Dentistry of New Jersey National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Use of non-internet cancer information No
Primary Use of the internet for cancer resources No
Primary Use of interactive technologies No
Primary Communication with treatment team and family members No
Primary Evaluation of internet resources No
Primary Changes in internet use over the course of treatment No
Primary Cross-sectional associations between patients' internet use and their individual, social, and professional network characteristics No
Primary Internet use and changes in patients' beliefs and emotional functioning No
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A